Scientific Contributions

Thought Leadership Presentation

In vitro ADME Inside Out: Sharing the Console

Drug development journeys are not created equal. As experienced in vitro ADME and DMPK scientists we're trained to deal with technical challenges, and we deftly adapt experimental designs and test systems to generate the right data answering the right questions. But programs can get derailed when internal and external stakeholders, who may or may not understand the complexity of a compound's ADME journey, have needs that are misaligned.

Failure to align at the outset, or to reevaluate as the data evolves, puts programs and timelines at risk, creating roadblocks to the goal of getting therapies to patients who need them. Designing experiments and programs tailored to the principal objectives of all major stakeholders is critical to success.

Date: Monday, Sept 16 
Time: 2:30 PM - 2:45 PM 
Room: Coral 1-3 (In Exhibit Hall)
Presenter: Joanna Barbara, PhD, BioIVT ADME Site Lead 

Industry-Sponsored Symposium

The Potential of Psychedelics for the Treatment of Neuropsychiatric Disorders

There is renewed interest in developing psychedelics such as psilocybin, LSD or MDMA as potential treatments for mental health disorders including major depression, post-traumatic stress disorder, and anxiety. This presentation will explain the different types of psychedelics that are being investigated as potential drugs, provide an overview of their long history of use and give insights into the market. In the second part, we will present current efforts to bring these potential drugs to the clinic with an emphasis on the pharmacology and current understanding of the mode of action as well as the ADME properties of these compounds. Lastly, we will briefly touch on potential challenges.

Date: Tuesday, Sept. 17 
Time: 7:15 AM - 8:15 AM 
Room: TBD 
Presenter: Tina Mueller, PhD, BioIVT Scientific Advisor for ADMET Services

Poster Session P33

An Evaluation of CYP and Non-CYP Reaction Phenotyping Study Trends from 2000-2023: A CRO Perspective

It has been well established that cytochrome P450 (CYP) enzymes are primarily involved in the metabolism of small molecule drugs and contribute to the potential risk of drug-drug interactions (DDIs). To reduce DDI liability, drug developers sometimes target non-CYP-mediated metabolism over CYP-mediated metabolism. Consequently, if drug developers attempt to design molecules that are metabolized by non-CYP enzymes, an increase of non-CYP enzyme evaluations in preclinical studies over time is expected. We analyzed sponsored reaction phenotyping studies implemented by XenoTech, now a BioIVT company, to evaluate whether there is a trend towards the development of drug candidates that are metabolized by non-CYP enzymes.

Date: Monday, Sept. 16 
Time: 1:30 PM - 2:15 PM 
Room: Poster Hall
Presenter: Tina Mueller, PhD, BioIVT Scientific Advisor for ADMET Services

Poster Session P327

Monocarboxylate Transporters 8 and 10: Siblings with Different Personalities

Monocarboxylate transporters 8 (MCT8) and 10 (MCT10) are members of the SLC16A family (SLC16A2 and SLC16A10, respectively) with high amino acid identity. To compare properties of these two transporters, we used OPTI-EXPRESSIONTM technology to develop assays for MCT8 and MCT10 in MDCK-II cells. An advantage of this assay system is that it allows investigation of transport into polarized MDCK-II cells from either the apical side or the basolateral side, as well as transcellular transport through the cell monolayer, providing flexibility in assay design. While these two closely related transporters share many properties, they also demonstrate key differences.

Date: Wednesday, Sept. 18 
Time: 12:30 PM - 1:30 PM 
Room: Poster Hall
Presenter: Mark Warren, BioIVT Senior Director of Transporter Assay Services